The Phase 1/2 study of bosutinib in ALS patients, sponsored by Kyoto University, represents a potential breakthrough in the treatment of amyotrophic lateral sclerosis (ALS), particularly for patients with SOD1 mutations. The market for ALS therapies is growing, with limited options currently available, primarily edaravone and riluzole. The successful development of bosutinib could position it as a competitive alternative, especially if it demonstrates significant efficacy and safety in the trial. The collaboration with multiple universities and Pfizer enhances credibility and may facilitate broader clinical acceptance and potential commercialization. However, the competitive landscape remains challenging, with ongoing research into novel therapies for ALS, necessitating diligent monitoring of trial outcomes and competitor developments.